In this video, health-care analyst David Williamson takes a closer look at Abbott Labs, which has seen its share of headlines this week. There was a big hepatitis C win, a high-profile drug failure, and a potential boost for its blockbuster. Amidst all this news, Wall Street has come out with a new recommendation on the stock. Watch and find out how this affects investors, and what may be the smartest way to play Abbott's spinoff.
David Williamson and The Motley Fool own shares of Johnson & Johnson. Max Macaluso has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.